Esperion Therapeutics (NASDAQ:ESPR) Shares Down 6.8% – What’s Next?

Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s share price fell 6.8% on Thursday . The company traded as low as $3.38 and last traded at $3.41. 3,604,589 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 6,164,863 shares. The stock had previously closed at $3.66.

Analyst Ratings Changes

A number of brokerages have commented on ESPR. Needham & Company LLC cut their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Esperion Therapeutics Stock Performance

The business’s 50 day moving average price is $2.29 and its 200-day moving average price is $2.20.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Wasatch Advisors LP raised its stake in Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after purchasing an additional 6,483,070 shares in the last quarter. Vanguard Group Inc. increased its holdings in Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after buying an additional 3,688,796 shares during the period. Geode Capital Management LLC increased its holdings in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the period. Marshall Wace LLP increased its holdings in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 2,087,635 shares during the period. Finally, State Street Corp increased its holdings in Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after buying an additional 99,802 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.